BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...Romberg as CEO. He was EVP of operations for the CSL Behring unit of CSL Ltd. (ASX:CSL). Kendrion...
BioCentury | Oct 9, 2020
Product Development

COVID-19 Quick Takes: Moderna won’t challenge vaccine IP, wins contract for mobile GMP manufacturing

...ITAC) study to treat hospitalized COVID-19 patients. Emergent BioSolutions Inc. (NYSE:EBS), Grifols S.A. (Madrid:GRF; NASDAQ:GRFS), CSL Ltd. (ASX:CSL...
...Projects Agency Gilead Sciences Inc. The European Commission Johnson & Johnson NIH National Cancer Institute Emergent BioSolutions Inc. Grifols S.A. Takeda Pharmaceutical Co. Ltd. CSL Ltd. Hologic...
BioCentury | Sep 10, 2020
Product Development

Takeda’s Weber expects expansion of precompetitive space, new alliance formats coming out of COVID-19: a BioCentury audio interview

...Alliance that Takeda is leading with CSL Ltd. (AXS:CSL...
BioCentury | Jul 15, 2020
Product Development

University of Queensland COVID-19 vaccine becomes seventh with CEPI funding to enter the clinic

...of nine CEPI-funded candidates to have entered human studies. In June, CEPI, Queensland and CSL Ltd. (ASX:CSL...
BioCentury | Jul 9, 2020
Product Development

CSL testing coagulation factor blocker in COVID-19 patients; plus vaccine deals and plasma trials

...testing a blood coagulation factor inhibitor for severe COVID-19. The CSL Behring unit of CSL Ltd. (ASX:CSL...
...of the double-blind, placebo-controlled trial is the incidence of tracheal intubation or death. In June, CSL...
...settings (see “Gilead Goes for Remdesivir Lung Delivery” ). BioCentury Staff garadacimab (CSL312) COVID-19 S-Trimer (SCB-2019) CpG 1018 Medicago-COVID-19-unknown COVID-HIG Veklury, remdesivir (GS-5734) CSL Ltd. Coalition...
BioCentury | Jul 1, 2020
Product Development

Accelerating the fight against COVID-19 with real-world data on tests

...the University of California Health System, and biopharmas including the CSL Behring unit of CSL Ltd. (ASX:CSL...
...they can persist. Steve Usdin, Washington Editor Friends of Cancer Research UnitedHealth Group Inc. Roche Aetion Inc. IQVia Holdings Inc. University of California CSL Ltd. LabCorp Quest...
BioCentury | Jun 27, 2020
Deals

Who’ll buy uniQure now?

...takeout target. Investors immediately soured on Wednesday’s deal in which uniQure N.V. (NASDAQ:QURE) granted CSL Ltd. (ASX:CSL...
...also been working on a hemophilia A gene therapy, AMT-180; however, when it announced the CSL...
...company went public on NASDAQ in 2014. Amanda Micklus, Senior Biopharma Analyst Novartis AG Gilead Sciences Inc. Biogen Inc. uniQure N.V. CSL Ltd. BioMarin...
BioCentury | Jun 25, 2020
Deals

June 24 Quick Takes: CSL pays $450M for uniQure’s hemophilia gene therapy; plus Merck-Yumanity, Editas, Compass-Olivia, Century-Empirica, Tetraphase-La Jolla

...CSL gets global rights to uniQure gene therapy CSL Ltd. (ASX:CSL) is paying $450 million up front...
...Pharmaceutical Co. Melinta Therapeutics Inc. AcelRx Pharmaceuticals Inc. Century Therapeutics LLC Empirica Therapeutics Compass Therapeutics Editas Medicine Inc. Yumanity Therapeutics LLC Merck & Co. CSL Ltd. uniQure...
BioCentury | Jun 20, 2020
Deals

Clinical scorecard for COVID-19: lessons from the first wave of controlled trials

...Sanofi (Euronext:SAN; NASDAQ:SNY) markets for rheumatoid arthritis; and mavrilimumab, an investigational GM-CSF inhibitor that CSL Ltd. (ASX:CSL...
BioCentury | Jun 18, 2020
Emerging Company Profile

Lassen emerges from Frazier with over $31M and a mAb for fibrosis and cancer

...is LASN01, a mAb against IL-11R that resulted from improvements to anti-IL-11R mAbs from CSL Ltd. (ASX:CSL...
...the target in exchange for an undisclosed equity stake and a board seat occupied by CSL...
...Therapeutics San Diego, Calif. Technology: Antibodies to treat fibrosis and cancer Origin of technology: CSL Ltd. (ASX:CSL...
Items per page:
1 - 10 of 495
BioCentury | Oct 17, 2020
Management Tracks

Merck KGaA’s Rossetti retires; plus moves at J&J, Innovent, eFFECTOR, Nautilus, Epirium and more

...Romberg as CEO. He was EVP of operations for the CSL Behring unit of CSL Ltd. (ASX:CSL). Kendrion...
BioCentury | Oct 9, 2020
Product Development

COVID-19 Quick Takes: Moderna won’t challenge vaccine IP, wins contract for mobile GMP manufacturing

...ITAC) study to treat hospitalized COVID-19 patients. Emergent BioSolutions Inc. (NYSE:EBS), Grifols S.A. (Madrid:GRF; NASDAQ:GRFS), CSL Ltd. (ASX:CSL...
...Projects Agency Gilead Sciences Inc. The European Commission Johnson & Johnson NIH National Cancer Institute Emergent BioSolutions Inc. Grifols S.A. Takeda Pharmaceutical Co. Ltd. CSL Ltd. Hologic...
BioCentury | Sep 10, 2020
Product Development

Takeda’s Weber expects expansion of precompetitive space, new alliance formats coming out of COVID-19: a BioCentury audio interview

...Alliance that Takeda is leading with CSL Ltd. (AXS:CSL...
BioCentury | Jul 15, 2020
Product Development

University of Queensland COVID-19 vaccine becomes seventh with CEPI funding to enter the clinic

...of nine CEPI-funded candidates to have entered human studies. In June, CEPI, Queensland and CSL Ltd. (ASX:CSL...
BioCentury | Jul 9, 2020
Product Development

CSL testing coagulation factor blocker in COVID-19 patients; plus vaccine deals and plasma trials

...testing a blood coagulation factor inhibitor for severe COVID-19. The CSL Behring unit of CSL Ltd. (ASX:CSL...
...of the double-blind, placebo-controlled trial is the incidence of tracheal intubation or death. In June, CSL...
...settings (see “Gilead Goes for Remdesivir Lung Delivery” ). BioCentury Staff garadacimab (CSL312) COVID-19 S-Trimer (SCB-2019) CpG 1018 Medicago-COVID-19-unknown COVID-HIG Veklury, remdesivir (GS-5734) CSL Ltd. Coalition...
BioCentury | Jul 1, 2020
Product Development

Accelerating the fight against COVID-19 with real-world data on tests

...the University of California Health System, and biopharmas including the CSL Behring unit of CSL Ltd. (ASX:CSL...
...they can persist. Steve Usdin, Washington Editor Friends of Cancer Research UnitedHealth Group Inc. Roche Aetion Inc. IQVia Holdings Inc. University of California CSL Ltd. LabCorp Quest...
BioCentury | Jun 27, 2020
Deals

Who’ll buy uniQure now?

...takeout target. Investors immediately soured on Wednesday’s deal in which uniQure N.V. (NASDAQ:QURE) granted CSL Ltd. (ASX:CSL...
...also been working on a hemophilia A gene therapy, AMT-180; however, when it announced the CSL...
...company went public on NASDAQ in 2014. Amanda Micklus, Senior Biopharma Analyst Novartis AG Gilead Sciences Inc. Biogen Inc. uniQure N.V. CSL Ltd. BioMarin...
BioCentury | Jun 25, 2020
Deals

June 24 Quick Takes: CSL pays $450M for uniQure’s hemophilia gene therapy; plus Merck-Yumanity, Editas, Compass-Olivia, Century-Empirica, Tetraphase-La Jolla

...CSL gets global rights to uniQure gene therapy CSL Ltd. (ASX:CSL) is paying $450 million up front...
...Pharmaceutical Co. Melinta Therapeutics Inc. AcelRx Pharmaceuticals Inc. Century Therapeutics LLC Empirica Therapeutics Compass Therapeutics Editas Medicine Inc. Yumanity Therapeutics LLC Merck & Co. CSL Ltd. uniQure...
BioCentury | Jun 20, 2020
Deals

Clinical scorecard for COVID-19: lessons from the first wave of controlled trials

...Sanofi (Euronext:SAN; NASDAQ:SNY) markets for rheumatoid arthritis; and mavrilimumab, an investigational GM-CSF inhibitor that CSL Ltd. (ASX:CSL...
BioCentury | Jun 18, 2020
Emerging Company Profile

Lassen emerges from Frazier with over $31M and a mAb for fibrosis and cancer

...is LASN01, a mAb against IL-11R that resulted from improvements to anti-IL-11R mAbs from CSL Ltd. (ASX:CSL...
...the target in exchange for an undisclosed equity stake and a board seat occupied by CSL...
...Therapeutics San Diego, Calif. Technology: Antibodies to treat fibrosis and cancer Origin of technology: CSL Ltd. (ASX:CSL...
Items per page:
1 - 10 of 495